NovoCure (NVCR) reported $161.27 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 20.6%. EPS of -$0.61 for the same period compares to -$0.45 a year ago.The reported revenue represents a surprise of -0.02% over the Zacks Consensus Estimate of $161.3 million. With the consensus EPS estimate being -$0.34, the EPS surprise was -79.41%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to dete ...

NovoCure (NVCR) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -79.41%. A quarter ago, it was expected that this oncology drug developer would post a loss of $0.34 per share when it actually produced a loss of $0.28, delivering a surprise of 17.65%.Over the last four quarters, the company ha ...

Company Overview - NovoCure Limited held its Q4 2024 Earnings Conference Call on February 27, 2025, at 8:00 AM ET, featuring key executives including Chairman Bill Doyle, CEO Ashley Cordova, and CFO Christoph Brackmann [1][3]. Conference Call Structure - The conference call began with an introduction by Ingrid Goldberg, who welcomed participants and outlined the agenda, which included a presentation followed by a question-and-answer session [2][3]. Financial Performance - The call aimed to review NovoCure's fourth quarter and full year 2024 performance, with accompanying slides available on the company's Investor Relations page [3].

NovoCure Limited (NASDAQ:NVCR) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Chairman Ashley Cordova - Chief Executive Officer Christoph Brackmann - Chief Financial Officer Frank Leonard - Executive Vice President & President, NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participants Jonathan Chang - Leerink Partners Jason Bednar - Piper Sandler Lei Huang - Wells Fargo Vijay Kumar - Evercore IS ...

Confidential © 2024 Novocu © 2025 re GmbH Novocure GmbH 1 © 2025 Novocure GmbH 2 GROW GBM LAUNCH LUNG DELIVER PIPELINE • •• © 2025 Novocu r e GmbH GmbH 3 ••• •• • © 2025 Novocure GmbH GmbH 4 | ✓ | | | | --- | --- | --- | | ✓ | ✓ | | | ✓ | ✓ | | | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ | | ✓ | • | • | | • | | | © 2025 Novocu r e GmbH 5 © 2025 Novocure GmbH 6 | U.S. DOLLARS IN MILLIONS | | Q4 2024 | | Q4 2023 | | FY 2024 | | FY 2023 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Net revenues | ഗ | ...

Financial Performance - Preliminary full year 2024 net revenues were $605.2 million, a 19% increase compared to the prior year[3] - Fourth quarter net revenues totaled $161.3 million, reflecting a 21% increase year-over-year[3] - The U.S., Germany, France, and Japan contributed $107.2 million, $17.7 million, $16.0 million, and $8.5 million to fourth quarter revenues, respectively[3] Patient and Treatment Updates - As of December 31, 2024, there were 4,126 total active patients on TTFields therapy globally[7] - 1,520 Optune Gio prescriptions were received in the fourth quarter, consistent with the same period in 2023[7] - As of December 31, 2024, there were 20 active NSCLC patients on Optune Lua[7] Regulatory Approvals and Designations - Optune Lua was approved by the FDA for the treatment of metastatic non-small cell lung cancer on October 15, 2024[7] - The FDA granted Breakthrough Device designation for TTFields therapy for brain metastases from non-small cell lung cancer in October 2024[7] Financial Position - Cash, cash equivalents, and short-term investments were $959.9 million as of December 31, 2024[7] Clinical Trials - Novocure plans to submit full data from the Phase 3 PANOVA-3 clinical trial for pancreatic cancer at an upcoming medical congress[13]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________ FORM 10-K ______________________________________________________________________ For the fiscal year ended December 31, 2024 or (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu ...

Core Viewpoint - The market anticipates NovoCure (NVCR) to report a year-over-year increase in earnings driven by higher revenues for the quarter ending December 2024, with actual results being crucial for stock price movement [1][2]. Financial Expectations - NovoCure is expected to report a quarterly loss of $0.34 per share, reflecting a year-over-year change of +24.4% [3]. - Revenue projections stand at $161.3 million, indicating a 20.6% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 2.03% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for NovoCure is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -27.91% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with a strong predictive power for positive readings [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically produced positive surprises nearly 70% of the time [8]. Historical Performance - NovoCure has beaten consensus EPS estimates in the last four quarters, with a notable surprise of +17.65% in the last reported quarter [12][13]. Industry Comparison - Fate Therapeutics (FATE), another player in the biomedical sector, is expected to report an EPS of $0.44 for the same quarter, with a year-over-year change of +2.2% and revenues expected to decline by 24.4% [17]. - Fate Therapeutics has seen a 0.2% increase in its consensus EPS estimate over the last 30 days, but its Earnings ESP stands at 3.82% combined with a Zacks Rank of 4, making predictions of an earnings beat challenging [18].

Core Insights - The life science industry has introduced a promising treatment for pancreatic cancer, potentially increasing long-term survival rates for patients [1] - Novocure and Zai Lab reported successful results from the Panova-3 study, indicating that their electric field-generating devices can enhance survival odds for pancreatic cancer patients [2] - Novocure's stock has surged 112% in 2024, driven by positive results in pancreatic cancer and the approval of its Optune Lua device for lung cancer treatment [3] Company Developments - Novocure's devices utilize electric fields to interfere with cell division, slowing tumor growth rather than destroying it [4] - The FDA approved Optune Lua for advanced-stage non-small cell lung cancer, although the trial results for chemotherapy patients were not statistically significant [5] - The Panova-3 trial involved 571 patients and showed that those receiving tumor-treating fields had a 33% higher chance of surviving 24 months compared to those receiving standard chemotherapy [6][7] Financial Performance - Novocure reported a 22% year-over-year revenue increase to $155.1 million, with an estimated revenue of $151,000 per patient annually [8] - The company is expected to see a significant increase in patient numbers, with around 67,000 new pancreatic cancer diagnoses anticipated in 2025, compared to 15,000 for glioblastoma [9] - The addressable patient population could increase approximately 18-fold if Novocure's devices gain regulatory approvals outside the U.S. [10][11] Market Position - Novocure's market capitalization is around $3.3 billion, which may be undervalued given its new lung cancer therapy and high pricing power [12] - The company is expanding its focus from glioblastoma to include lung and pancreatic cancer, reporting positive adjusted EBITDA but still facing GAAP losses [13] - While Novocure's stock presents risks, a successful launch of Optune Lua could lead to substantial profits that the market may not currently anticipate [14]

Group 1 - The article discusses the investment opportunities in the healthcare sector, particularly focusing on innovative companies developing breakthrough therapies and pharmaceuticals [1]. - The leader of the investing group Compounding Healthcare emphasizes the importance of catalysts for potential acquisitions in the biotech industry [1]. - The group offers several features including model healthcare portfolios, a weekly newsletter, and a daily watchlist for investors [1]. Group 2 - The analyst has a beneficial long position in the shares of NVCR, indicating confidence in the company's future performance [2]. - The article is based on the author's own opinions and does not involve compensation from any company mentioned [2]. - There is no business relationship between the author and any company whose stock is discussed, ensuring an unbiased perspective [2].